Tissue Repair Ltd · ASX:TRP
Tissue Repair — Corporate Update (July 2024)
27 slides from Tissue Repair's corporate update, Jul 31, 2024
Slide 1: Progress & Company Update
For personal use only Tissue Repair Limited Progress & Company Update Tony Charara Co-founder and Executive Director
Slide 2: Achievement of prospectus objectives are within sight
Achievement of prospectus objectives are within sight For personal use only Phase 3 first Secured TGA Device application for patient expected Sites secured in +100% sales approval for Glucoprime ahead of drug growth last quarter September 30 principle Glucoprime® as a approval Listed Medicine Device
Slide 3: Quick recap on Tissue Repair Ltd
Quick recap on Tissue Repair Ltd Tissue Repair is a Phase 3 biotechnology company with a technology platform applicable to all wounds in animals or humans. Proprietary patent protected novel immunomodulating molecule The Company is fully funded to conduct two global pivotal trials for its drug Large
Slide 4: TR Pro+ - Initial Technology Commercialisation
TR Pro+TM - Initial Technology Commercialisation Real world Feedback that includes more than 50 testimonials from clinicians, doctors, For personal use only cosmetic nurses and dermal therapists Dr Olivia Fox General Practitioner Wylah Skin Aesthetics 4
Slide 5: Dermatologist testimonial
Dermatologist Dr David Scott Your Skin Clinic For personal use only 5
Slide 6: Registered nurse testimonial
Jaci Issacs Registered Nurse Clinical Director Art of Aesthetics For personal use only 6
Slide 7: We have been laying foundations to scale
We have been laying foundations to scale Last quarter sales up over 100% in the Quarter (150-200 clinics) • The priority is preparing for scaling via partners and less about sales growth -> primary focus is clinic distribution. • Still small numbers given very limited investment, but management beli
Slide 8: TR Pro+ approved as a TGA listed medicine
TR Pro+TM has been approved as a TGA listed medicine . . . a significant development The TGA Listing allows Tissue Repair to expand into a broad range of additional dermatology and aesthetic indications For personal use only A HYDROGEL THAT ENHANCES SKIN HEALING 0.1% Glucoprime® - Proprietary Existi
Slide 9: Fractional laser skin resurfacing example
Some examples . . . Fractional laser skin resurfacing Other aftercare TR Pro+ For personal use only A split face procedure shows the profound impact of TR Pro+TM at 18 hours where the skin is significantly less red and does not have the raised circles from the laser. The patient could not believe th
Slide 10: Morpheus8 (RF skin needling)
Morpheus8 (RF skin needling) For personal use only The effects of TR Pro+TM were apparent in as little as one hour, with less visible redness. The patient reported almost instantaneous cooling and soothing that reduced the pain and tingling compared to prior procedures.
Slide 11: Chemical peel
Chemical peel At 18 hours, and after For personal use only the application of TR Pro+ TM, the skin was significantly less flaky and there was little evidence of the peel procedure the day before. As well as reduced redness and irritation, TR Pro+ TM was able to significantly reduce the patient downt
Slide 12: Hard to heal sore - BCC removal
Hard to heal sore - BCC removal (basal cell carcinoma) For personal use only Elderly man had a BCC removed from his lower leg. After 5 days the previously infected wound appeared healthy Day Day 5 and close to healed. 1 Patient indicated this healing was significantly quicker and less painful than p
Slide 13: Minor head wound
Wounded skin For personal use only Minor headwound impact. After 48 hours, this head wound was noticeably smaller and by 7 days there was virtually no sign of the damaged skin.
Slide 14: Superficial burn
Superficial burn For personal use only After 5 days without using TR Pro+ TM this burned skin still appeared red and painful. Three days of treatment with TR Pro+ cooled and soothed the wound and left the skin looking healthy.
Slide 15: TR Pro+ used as glide solution during needling
TR Pro+ Untreated TR Pro+TM used as the glide solution during needling For personal use only TR Pro+ TM was infused during the needling procedure on the right-hand side of the face while the other side was untreated. The treated side is clearly less red and according to the client had less pain and
Slide 16: Lipoma excision
Lipoma excision The TR Pro+ TM was applied For personal use only from day 3, three times a day with a clean cotton tip. There was no post heal itching, inflammation or sensitivity.
Slide 17: TGA listed TR Pro+ revenue potential in Australia
TGA listed version of TR Pro+TM has the potential of to be a $10m- $50m revenue business in Australia alone, assuming a 10% - 20% market penetration rate (illustrative only) Tissue Repair may not enter these markets on its own would look to partner off the back of a TGA product For personal use only
Slide 18: TR987 Phase 3 Drug Trial Initiation
TR 987 Phase 3 Drug Trial Initiation First patient randomisation For personal use only scheduled for 30 September 2024 18
Slide 19: TR987 Phase 3 trial update
TR987® Phase 3 trial update First patient targeted to be randomised by Key trial numbers 30 September (screening in • 2x Phase 3 trials mid-September) For personal use only • BG002 (US) 300 patient trial Trial recruitment period of 18 months from • BG003 (Primarily Australia) 300 patient trial initi
Slide 20: Some delays but prospectus objectives are being met within the funding envelope
Some delays but prospectus objectives are being met within the funding envelope Additional work on the protocol and optimizing trial design • Control arm will be standard-of-care and not vehicle gel, to support reimbursement and health economics application • The Phase 3 trial is fully For personal
Slide 21: The Phase 3 opportunity: 20% delta in VLUs
The Phase 3 opportunity is exciting because a 20% delta in VLUs in pivotal trials has not previously been demonstrated Protocol and optimized trial design • Control arm will be standard-of-care and not vehicle gel, to Adj % Diff support reimbursement and health economics application Per Keyprotocol
Slide 22: New analysis on mechanism of action at UniSA
New analysis on mechanism of action at the University of South Australia (UniSA) Research by UniSA demonstrates how Glucoprime® can modulate the balance Lower IL-10 at day between pro- and anti-inflammatory stages during healing 7 means less For personal use only inflammation At day 1 we know there
Slide 23: TR Pro+ facilitates the transition of M1 to M2 macrophages
TR Pro+TM facilitates the transition of M1 to M2 macrophages* This MoA is powerful and has application to a significant number of wound types and dermatologic indications Total M1 For personal use only macrophages macrophages Over double Proportion of M1 and M2 M2 macrophages the number of M2-type m
Slide 24: A case study: Oneness Biotech
A case study: Oneness Biotech's primary product is Fespixon currently in trials in the USA at Phase 3 in DFUS with a US2.2b market capitalisation. . . TR is trading below cash backing. Market ascribed a valuation of Shares on Issue 60,464,843 US$2.2b down For personal use only from recent highs Opti
Slide 25: In summary Tissue Repair has a significant opportunity ahead
In summary Tissue Repair has a significant opportunity ahead with a track record of achieving goals and navigating challenges Generated revenue now with strong growth TR Pro+TM Australian TAM +AUD100M TGA approved with marketing commencing Q1 2025 Founder strategy has Medical and aesthetic wounds in
Slide 26: Small highly experienced seasoned team of executors
Small highly experienced seasoned team of executors Tony is a co-founder of Tissue Repair. He has been actively involved in the Company’s clinical development program, across its two-phase 2B trials, commercialisation strategy, IP, Tony Charara manufacturing, analytical development and overall opera
Slide 27: Important notice and disclaimer
Important notice and disclaimer This presentation (Presentation) is dated 18/09/2023 and has been prepared by Tissue Repair Ltd (ACN 158 411 566) (Tissue Repair or the Company). Information in this Presentation For personal use only The information in this Presentation is of a general background nat